Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 16Terminated 5Recruiting 5Active not recruiting 4Withdrawn 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Leiomyosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × ADI PEG20 × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

NCT06085729 2026-04-02

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT05317819 2025-12-18

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Polaris Group

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06034977 2023-09-13

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Chang Gung Memorial Hospital

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡